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This study analyzed whether human keratinocytes ("KC) 
express conventional HLA class-! molecules as detected 
by class-1-specific cytotoxic T lymphocytes (CTL), and 
whether exposure of KC to interferon-gamma (IFN -g) is 
required for CTL recognition. Basal KC grown in serum-
free medium and exposed to recombinant IFN-g for 24 -
96 h were used as targets in 51 Cr-release assays. Target-cell 
susceptibilities to lysis were compared by analyzing the lytic 
unit (LU) activity of a given CTL population against IFN-g-
treated and untreated KC. CTL effectors were cloned from 
alloantigen-primed cultures by limiting dilution in the pres-
ence of antigenic B lymphoblastoid cells (BCLL) and IL-2. 
These T -cell clones lysed appropriate BCLL and PHA blasts 
but not third-party BCLL or K562. Lysis of antigenic BCLL 
was specifically blocked by antibodies against CD3 or class-I 
antigens. Specificity of the clones for conventional class-! 
antigen was demonstrated by cytotoxicity tests employing a 
panel ofHLA-typed BCLL. The clones specifically lysed KC 
D etail ed knowledge oflymphocyte-keratinocyte in-teractions would improve our understanding of both normal and pathological epidermal immune responses, and could shed light on mechanisms of inflammatory disease in other organs. Lymphocytes 
and keratinocytes (KC) can interact via direct intercellular contact. 
Direct contacts that culminate in KC lysis are clearly important for 
understanding epidermal disease. Several types of cellular effectors 
mediate KC lysis. For example, monocytes and lymphocytes lyse 
TNP-derivatized human KC, and these same cell subsets medtate 
antibody-dependent cytotoxicity against KC [1]. In addition, IL-2-
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Abbreviations: 
A-BCLL: BCLL from individual A 
A-KC: KC from individual A 
BCLL: 13-cel\ lymphoblastoid ce ll line 
CTL: cytotoxic T lymphocyte 
JCAM-1: intercel lular adhesion molecule 1 
IFN-g: interferon gamma 
KC: kcratinocytes 
syngeneic with the original effector immunogen, and lysi~ 
was also blocked by anti-class-I antibodies. The effect o~ 
IFN-g treatment was to increase KC susceptibility to lysis by 
these clones. From 3- 25 times more LU were measure~ 
against IFN-g-treated KC than against nontreated KC, anq 
the degree of enhancement was similar for KC treated with, 
concentrations ofiFN-g ranging from 2.5-200 U jml. Thi~ 
effect of IFN-g treatment on KC lysis by CTL, which wa 
detected after only 24 h at all doses tested, emphasizes the 
potential role of IFN-g in enhancing CTL-mediated anti, 
viral epidermal immunity and in exacerbating epidermal dis, 
ease mediated by specific lytic T cells. In addition, the finding 
that normal human KC can be recognized by MHC class-!, 
specific CTL demonstrates that KC do express conventional 
class-I antigens and that KC lysis by CTL can occur indepen-
dently of exogenous cytokines. J Invest Dermatol 95:224 ~ 
228, 1990 
stimulat~d peripheral blood leukocytes can lyse both autologous an~ 
allogenetc KC [2] . In both of these cases, KC lysis appears to mvolv~ 
ef."ector cell recognition that is not regulated by m;Uor histocompat\ 
ibility (MHC) products. Evidence that KC may also be susceptibl~ 
to MHC-specific lysis comes fro m the finding that alloreactive T1 
cell lines can distinguish autologous and allogeneic human KC [3t 
It has become mcreastngly clear that these direct lymphocyte/KQ 
interactions can be influenced by, and can lead to the secretion of 
soluble mediators termed cytokines [4- 6J. Thus, direct and indirec~ 
pathways of lymphocyte/KG interaction are highly interdepeu, 
dent. N evertheless, it has proved difficult to analyze the role o~ 
cytokines in pathological lymphocyte/KC interactions in vivo
1 
where stmtlar effector lymphocytes and cytokines appear able 
cause or prevent disease, depending on factors that are not full)' 
understood. · 
Interferon gamma (IFN-g) is a secreted product of activated'}\ 
lymphocytes and natural killer cells, which ,.erofoundly affec~ 
human KC growth, antigenicity, and structure [7 -10]. The repol"\ 
that human KC must be exposed to IFN-g to be lysed by HLA-spe-.. 
cific cytotoxic T lymphocytes (CTL) implies that KC do not nor, 
mally express functionally relevant levels of classical HLA mole-.. 
cules (3}. Deficient K.C expression of class-I HLA molecules would, 
be compatible with the intriguing hypothesis that T cells use differ, 
ent receptors and restricting elements for recognizing epithelia\ 
cell s than for other cell types [11] . It is somewhat surprising tha\ 
direct evidence of HLA-A, -B, or -C expression by KC is lackin 1 
especially as epidermal Langerhans cells express only low levels o~ 
HLA antigens [12] . It is thought that KC in the vicinity of virus, 
specific, antigen-specific, or alloantigen-specific T lymphocytes~ 
exposed to IFN-g in vivo [13, 15). Exposure to IFN-g can arrest K 
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proliferation, affect HLA class-! antigen expression, and induce de 
novo expression of KC HLA class-II antigens and adhesion mole-
cules [5,8-10]. Therefore, IFN-g could affect KC lysis mainly by 
inducing de novo expression of MHC antigens or by altering ex-
pression ofKC adhesion molecules [1 6,17]. Whatever its molecular 
basis, this putative requirement for IFN-g in CTL-mediated KC 
lysis leads to the prediction that anti-IFN-g therapy should com-
pletely block epidermal disease caused by specific CTL. These issues 
led us first to seek functional evidence of KC expression of conven-
tional class-I antigens, and then to assess whether IFN-g treatment 
of KC is required for their subsequent lysis by CTL. 
MATERIALS AND METHODS 
Cytokines and Antibodies Recombinant human IL-2 (riL-2) 
was kindly provided by Hoffman LaRoche, Inc. (Nutley NJ). Re-
combinant human IFN-g was generously supplied by Schering 
Corp. (Bloomfield, NJ) and contained 100-200 endotoxin units 
per 3.5 X 106 units of IFN-g as supplied. Mouse hybridoma anti-
body against HLA class I (W6/32) was the gift of Dr. D. Geraghty, 
and antibodies against HLA class II (P4.1) and CD3 (64.1) were 
gifts of Dr. P. Martin (both of this institution). These IgG2a anti-
bodies were purified from ascitic fluids by protein A-Sepharose 
chromatography [18] . 
Keratinocyte Culture Basal KC were released by trypsinizing 
epidermal sheets obtained by suction biopsy of adult skin or by 
overnight Dispase digestion of neonatal foreskin as previously de-
scribed (10]. After removing aggregates by filtering through Nytex 
mesh, KC were cultured in MCDB 153 serum-free medium with 
modifications (19,20] at 37"C in humidified 7% C02 93% air. 
Medium was reconstituted from powdered MCDB 153 medium 
base, vitamins, and trace element components (Irvine Scientific, 
Santa Ana, CA). Additives were from Sigma (St. Louis, MO) except 
for 0 -phosphoethanolamine (Aldrich, Milwaukee, WI), bovine pi-
tuitary extract (University of Colorado, Boulder, CO), and human 
recombinant epidermal growth factor prepared and generously pro-
vided by C . Georges-Nascimento (Chiron Corp., Emeryville, CA). 
Calcium concentrations were monitored by flame photometry. KC 
were used at second through fourth passage (2-4 weeks of culture). 
KC were sometimes cultured in medium containing IFN-g (2.5-
500 U / ml) for 24-96 h before used as assay targets. 
Effector Cells Cytotoxic T-celllines were generated by co-cul-
turing Ficoll-Hypaque purified peripheral blood mononuclear cells 
with irradiated, allogeneic B lymphoblastoid cell s (BCLL) for 10 d 
in RPMI1640 medium containing 15% pooled human serum 
(c1640). Cells were cloned at limiting dilution in Terasaki wel ls in 
the presence of additional irradiated (4500 rad) specific BCLL and 
up to 20 U /ml of riL-2. Proliferating cells were transferred to larger 
wells, expanded by 7 to 10-day stimulation cycles with BCLL and 
IL-2, and aliquotted and frozen in 95% fetal bovine serum (FBS). 
Thawed clones were restimulated with allogeneic BCLL for 7 days 
before assay. 
Cytotoxicity Assay Effector cells were washed twice and resus-
pended in c1640 at 1 -2.4 X 106 cells/mi. The initial cell suspen-
sions and five additional serial twofold dilutions thereof were plated 
in triplicate sets in 96-well round-bottom plate wells (100 ,uljwell) 
(Flow Laboratories, McLean, VA). In some cases, 20 ,ugjml of anti-
body was added to effector cell suspensions and the diluent. T arget 
cells in RPMI1640 with 30% human serum were radiolabeled by 
incubating them at 37° C for up to 75 min with an equal volume of 
51 Cr (DuPont-New England Nuclear) in PBS, washed thrice in 
RPMI1640 containing 10% fetal bovine serum, and resuspended to 
2 X 104 cells/ml (KC) or 4 X 104 cells/ml (BCLL) in c1640. In 
some cases, target-cell suspensions were incubated for 20 min on ice 
in 1 ml of antibody (40 ,ug/ ml) in c1640, diluted to their assay 
concentrations in c1640, and the same antibody added to a concen-
tration of 10 ,ug/ml. Target cells (100 ,ul) were added to wells 
containing effector cells, medium only, or 0.2% NP-40 detergent. 
Plates were centrifuged 2 min at 15 X g, floated for 5 min in a 37 oC 
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water bath, and incubated 4 h in humidified 7% C02 93% air. 
Plates were centrifuged 2 min at 200 X g, and 100 ,ul of each well 
supernatant assayed for radioactivity in a Packard gamma counter. 
Data Analysis Percent specific lysis (SL) values were calculated 
by using the formula, %SL = ((ER- SR)/ (MR- SR)J X 100%, in 
which ER, SR, and MR represent supernatant radioactivity in wells 
containing effectors, medium only, or detergent, respectively. A 
computer program generously provided by Dr. H. Pross (McGill 
University, Ontario, Canada) was used to calculate lytic units (LU) 
per 106 effectors for each effector/target combination according to 
an exponential fit formula [21]. LU calculated for 10% or 20% 
levels of lysis are presented as LU 10 or LU20 , respectively. Both an 
assigned maximum potential percent lysis value of 80o/o and a value 
computed from the data by an iterative procedure were used in LU 
calculations. This was done to monitor possible induction by IFN-g 
of KC subsets that could be totally refractory to CTL lysis. Differ-
ences in LU of a giv~n effector population for nontreated IFN-g-
treated KC were constdered to reflect dtfferences in the susceptibil-
ity of tl,1ese targets to lysis. 
RESULTS 
Effector cells were cloned from in vitro-primed PBMC in the pres-
ence of irradiated BCLL from the same individual ("A") who sup-
plied the priming PBMC. The function and specificity of selected 
anti-A clones were analyzed to identify and define cellular reagents 
needed to assess KC HLA expression and sensitivity to IFN-g. Re-
sults with two clones are described. These clones were specific for 
A-BCLL and did not lyse syngeneic BCLL. Table I shows that lysis 
of A-BCLL by both clones involved HLA class-! antigens, as lysis 
was blocked by W6/32 antibody. Inhibition oflysis by W6/32 was 
specific, as anti-HLA-DR antibody that could also bind the targets 
had no effect on lysis. Anti-CD3 antibodies inhibited BCLL lysis, 
suggesting that class-I antigen recognition by these clones involves 
T-cell receptors, whose transmembrane signaling occurs via the 
CD3 molecular complex. 
The observed inhibition by W6/32 of A-BCLL lysis was consist-
ent with class-I spectfictty of the CTL clones. However, as W6/32 
crossreacts with nonclassical HLA antigens [22], further evidence of 
clone specificity for classical HLA-A, -B, or -C antigens was needed. 
The functional specificity of the clones was therefore defined by 
using a panel of HLA-typed BCLL target cells which share known 
HLA antigens with A-BCLL. As shown in Table II, clones 15 and 4 
lysed HLA-B7-positive BCLL but did not lyse BCLL sharing other 
class-! or class-TI antigens with A-BCLL. Both clones also lysed 
other HLA-B7 -positive BCLL and failed to lyse other HLA-B7-
negative BCLL in two addi tional typing experiments. Also, both 
clones were consistently inactive against K562 in these typing assays 
and in at least six previou~ assays used to monitor clonal expansion 
(data not shown) . Collecttvely, these results indicate that the cyto-
toxic T -cell clones 15 and 4 recognize classical class-I molecules 
(i .e., HLA-B7) on target BCLL. 
We next asked whether untreated KC could be recognized by 
these HLA-specific CTL, and whether IFN-g pretreatment of KC 
Table I. Lysis of A-BCLL by CTL Clones 15 and 4• 
Antibody 
in Assay Clone 15 Clone 4 
17 5 
W6/ 32 2 0 
P4.1 16 5 
64.1 1 1 
• Lysis of A-BCLL by CTL clones 15 and 4 involves class I and CD3. The ability of 
monoclonal antibodies against class I (W6/ 32), class II (P4.1) , or CD3 (64.1) to inhibit 
lysis of A-BCLL by cloned CTL was tested. Results arc expressed as lytic units (LU20 , 
see Materials and Methods). Lysis of A-BCLL by these clones was inhibited by W6/32 
and 64.1 in two addi tional experiments. Results in all tables arc based on data from 
assays performed in triplicate at each of six effector-to-target ratios. 
b No antibody. 
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Table II. CTL Clones 15 and 4 Specific for HLA-B,7• 
HLA Ags Shared with A-BCLL % Specific Lysis6 
BCLL Target A29 B7 B44 DR7 DQw2 w53 Clone 15 Clone{ 
A X X X X X X 50 55 
B X X X X <i <t 
c X 52 14 
D X <i <i 
E X X X < 1 < 1 
' BCLL from individuals B, C , D, and E, who share the indicated HLA specifiCities with A-BCLL (derived from the PBMC used to prime for CTL expansion), were used as cargen 
for cloned CTL In 51 Ct-release assays. Positive results are underlined. 
I Effector- target ratio, 50 : 1. 
would affect their susceptibility to CTL lysis. A-KC and third-party 
KC were cultured for 72 h in the presence or absence of recombi-
nant human IFN-g before used as targets in 51 Cr-release assays in 
parallel with A-BCLL targets. The results of two experiments illus-
trate the main findings consistently observed throughout this study 
(Table III) . First, the clones lysed A-KC but not unrelated KC. This 
indicates that lysis of A-KC is specific and that these KC express 
sufficient HLA-B7 to be recognized by specific al!oreactive CTL. 
Second, the CTL clones lysed both IFN-treated and nontreated 
A-KC. This demonstrates that IFN-treatment is not an absolute 
requirement for lysis of KC by alloreactive CTL. Third, IFN-g 
treatment considerably increased the susceptibility of A-KC to CTL 
lysis. Similar results were obtained in six additional experiments in 
which these and other CTL clones specifically lysed KC from other 
donors. That is, specific lysis was observed for both nontreated and 
IFN-g-treated KC, and the susceptibility of IFN-g-treated KC to 
lysis by clones 4 and 15 was always increased compared with un-
treated KC. Increased susceptibility was evident whether LU were 
calculated using computed or assigned values for maximum lysabil-
ity [21], which excludes the possibility that the apparent increase in 
susceptibility of IFN-g-treated KC was solely due to an increased 
proportion of susceptible targets. The enhancement was also not 
attributable to selective toxicity of IFN -g for a KC population that 
normally resists lysis, since treatment with these doses of IFN-g 
halts KC proliferation without markedly affecting KC recovery or 
viability [3, 10]. The LU20 for the six, single-dose experiments aver-
aged twofold or sevenfold higher against IFN-treated KC depend-
ing on whether assigned or computed values for potential maxi-
mum lysis were used in the calculation (see Materials and Methods, 
data not shown). Additional experiments were performed to learn 
what IFN-g dosages and treatment intervals would lead to enhanced 
KC lysis. When KC were treated for 1 or 3d with 2.5, 10, 40, or 
200 U /ml of IFN-g before used as CTL targets, all of these treat-
ment schedules were associated with markedly enhanced KC lysis 
(Table IV). Dose dependence of the enhancement was not observed 
for KC treated for 1 d with these concentrations ofiFN-g, whereas 
treatment for 3 d was associated with reduced levels of enhance-
Table III. KC Susceptibility to CTL Lysis• 
51 Cr-Target 
A-KC Irrel. KC A-BCLL 
IFN Pre-Rx-> 
(500 U/ml) No Yes No Yes No 
Expt. 1 
191 < 0.2 < 0.2 95 Clone 15 85 
Clone 4 151 220 < 0.2 < 0.2 163 
Expt. 2 
Clone 15 37 178 < 0.2 3 239 
Clone 4 2 11 < 0.2 < 0.2 30 
• KC susceptibility to CTL lysis is augmented by, but docs not require, pretreatment 
of KC with IFN-g. CTL clones were assayod against KC that were pretreated for 96 h 
with 500 U /ml of recombinant human IFN-g or control medium. Results are expressed 
as lytic units (LU20 , see Materials aud Methods) . 
ment at the higher IFN-g doses. Similar enhancement of KC lysis 
after 24 h of low-dose treatment with IFN-g was observed in a 
second experiment. Finally, specific lysis of nontreated KC could 
be inhibited by W6/32, thus providing additional evidence that 
CTL lysis of KC is class I- specific as was the case for BCLL targets 
(Table V) . 
DISCUSSION 
The main conclusions from these studies are that: (1) cultured 
human KC can express classical HLA class-I antigens as defined by 
specific CTL lysis; and (2) lysis of KC by such CTL can be enhanced 
by prior short-term KC exposure to low doses of IFN-g. These 
conclusions are based on the results of functional assays in which 
cloned, HLA-specific CTL rather than bulk T -cell lines were used 
as effector-cell populations. Cloned CTL were used to avoid the 
potentially confusing effects of polyspecific effector populations. 
For example, T -cell lines might include effectors specific for class ll 
that could only recognize IFN-g-treated KC, as has been suggested 
to account for skin-graft rejection by CD4+ cells [23] . Similarly, 
T-~elllines could include effectors specific for nonclassical HLA 
antigens that could interfere with analysis of classical HLA class-! 
antigen expression by KC. 
Expression· of conventional class-! antigens by KC has not pre-
viously been demonstrated, although it is well-known that major 
histocompatibility complex antigens are expressed by mouse mela, 
nocytes and hair follicle cells [24] and that human KC stain for the 
class-1-associated protein, beta-2 microglobulin. As KC were not 
lysed by a variety of complement-fixing anti-HLA alloantisera us 
for histocompatibility typing, we addressed this issue by using func. 
tionally characterized cellular reagents. Lysis of KC by allele-spe-
cific CTL is currently the strongest evidence for KC expression of 
conventional class-I polymorphic HLA antigens. Of course, these 
results do not exclude possible KC expression of nonclassical class-! 
molecules whose genes are transcribed in skin [25], and the respec, 
rive roles of KC classical and nonclassical class-I antigens in vivo 
remain to be clarified. 
KC lysis by HLA class !-specific CTL was enhanced by, but did 
not require, IFN-g pretreatment. This quantitative effect ofiFN-g 
on KC lysis by CTL differs from the qualitative effect suggested by a. 
prev1ous study [3] . Use of heterogeneous cytotoxic cell Jines an~ 
Table IV. Time and Dosage Requirements for IFN-g-Induced 
Enhancement of KC Lysis by CTL• 
IFN-g (U/ml) 
KC Treatment 
(days) 0 2.5 10 40 20ij 
Clone 4 1 90 657 601 473 6~ 
3 102 335 203 258 19~ 
Clone 15 1 22 293 265 253 29(\ 
3 23 256 132 156 10) 
'Treatment with !FN-g was staggered to allow simultaneous assay of all targ<n 
Results expressed as LU 10/106 effectors. 
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Table V. Lysis of Untreated KC by Clones 15 and 4 Inhibited 
by Anti-Class-1 Antibodies• 
Ab Added 
Clone 15 
Clone 4 
A-KC +No Ab 
34 
5 
51 Cr-Target 
A-KC+W6/32 
12 
2 
• Results are expressed as LU20/106 effectors. Lysis of antigenic KC by these clones 
was inhibited by W6/32 over a range of£: T ratios in th e three experiments performed. 
quite different KC culture conditions for this previous work may 
account for the difference. As was suggested above, the presence of 
class Il-specific CTL in uncloned cell lines assumed to be class 
!-antigen-specific could lead to overestimates of the effect of 
IFN-g on susceptibility to class !-specific lysis, since class-II anti-
gens would only be expressed by IFN-g-treated KC. Alternatively, 
cloned CTL may differ from primary.or secondary CTL in terms of 
the requirement for IFN-g treatment of their KC targets. This latter 
possibility is being tested. 
The mechanism by which IFN-g treatment enhances KC lysis by 
class !-specific CTL is unknown, but IFN-g treatment of other cell 
types can also increase their susceptibility to CTL lysis (26,27]. 
Induction of class-1 target antigens was proposed to explain en-
hanced lysis ofiFN-g -treated KC by T -cell lines (3]. If this mecha-
nism is involved here, then it would be the number of class-I mole-
cules per cell rather than per unit plasma membrane that influences 
lysis, because whatever increases in KC class- I expression that occur 
after IFN-g treatment can be attributed to KC enlargement (10,28]. 
Arguing against a major ro le for class I induction is the finding that 
KC lysis was enhanced after only 24 h of treatment with low doses 
of IFN-g (Table IV), whereas MHC induction by IFN-g typically 
requires 48 h even when high doses of IFN-g are used (29,10]. A 
mechanism that is more consistent with the kinetics of enhance-
ment could involve IFN-g-induced KC ICAM-1 expression. 
ICAM-1 mediates the increased nonspecific adhesion between 
IFN-g-treated KC and T lymphoblasts (5], and CTL lytic efficiency 
is increased by receptor-regulated binding ofT-cell LFA-1 to target 
cell ICAM-1 [17]. Furthermore, ICAM-1 expression by cultured 
KC can be induced by 24 h ofiFN-g treatment (5,29]. Anti-ICAM-
1 or anti-LFA-1 ascitic fluids were able to inhibit lysis of IFN-g-
treated KC by IL-2-treated lymphocytes, suggesting that ICAM-1/ 
LFA-1 interactions may faci litate lysis of IFN-g-treated KC by 
non-MHC-restricted cytotoxic effectors [2]. Effects of IFN-g on 
KC membrane synthesis and repair could also render KC more 
sensitive to CTL-mediated damage. Finally, IFN-g treatment may 
alter the profi le of HLA-associated self-peptides of KC to more 
closely resemble those of the original BCLL immunogen. This 
mechanism could increase the antigenicity of the KC without in-
creases in class-I heterodimer expression. The idea that class I-
specific CTL might discriminate between allogeneic KC and BCLL 
from the same individual would be compatible with recent demon-
strations of cell-type or species-specific variations in the alloanti-
genicity of cells expressing similar amounts of the same major histo-
compatibility molecules (30,31 ]. More work is needed to sort out 
which, if any, of these processes is most important. 
It seems likely tlut IFN-g produced by immune cells during 
cutaneous immune responses could faci litate CTL-mediated lysis of 
antigenic KC. Concentrations of IFN in excess of those that en-
hance KC lysis in vitro have been measured in pathological epider-
mal blister fluids [32]. If one assumes that induction of KC class-II 
antigen in vitro and in vivo requires similar amounts ofiFN-g, then 
KC are probably exposed to sufficient IFN-g for enhancement of 
CTL lysis in diseases associated with KC class II expression, since 
class II induction in vitro requires at least as much IFN-g as the 
enhancement of lysis reported here. In vitro treatment of KC does 
not foster nonspecific lysis by CTL, nor does it increase KC suscep-
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tibility to lysis by IL-2 activated killer cells (this article and unpub-
lished data), suggesting that its major effect in vivo would be on 
antigen-specific effector/KC interactions . Based on these findings, 
IFN-g could affect epidermal immunity through at least two path-
ways: one involving its role as a positive modulator of specific T-cell 
recognition, and the other involving its cytostatic action on normal 
KC. Both pathways would faci litate elimination of virus-infected 
KC during a normal immune response. The idea that KC exposure 
to IFN-g could exacerbate CTL-mediated skin disease suggests that 
epidermal damage in these cases might be minimized through ther-
apeutic control of KC exposure to IFN-g by specific antibodies or 
receptor antagonists. 
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